Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor–stroma ratio in colon cancer

• Published in: ESMO open Vol. 9; no. 4; p. 102988
• Main Authors: Polack, M., Smit, M.A., van Pelt, G.W., Roodvoets, A.G.H., Meershoek-Klein Kranenbarg, E., Putter, H., Gelderblom, H., Crobach, A.S.L.P., Terpstra, V., Petrushevska, G., Gašljević, G., Kjær-Frifeldt, S., de Cuba, E.M.V., Bulkmans, N.W.J., Vink, G.R., Al Dieri, R., Tollenaar, R.A.E.M., van Krieken, J.H.J.M., Mesker, W.E., Petrushevska, Gordana, Bogdanovska, Magdalena, Zdravkoski, Panche, Antovic, Svetozar, Dzambaz, Darko, Karagjozov, Panche, de Cuba, Erienne M.V., Beverdam, Frédérique, Jansen, Jan, Vermaas, Maarten, Gašljević, Gorana, Kjær-Frifeldt, Sanne, Lindebjerg, Jan, Strous, Maud, Vogelaar, Jeroen F., Bulkmans, Nicole W.J., van Baarlen, Joop, Mekenkamp, Leonie, Hoekstra, Ronald, Sie, Mark, Cuatrecasas, Miriam, Simonetti, Sara, Rodrigo, María Teresa, Sanz, Iván Archilla, Guerrero Pineda, Jose, Leeuwis-Fedorovich, Natalja E., Talsma, Koen A., Souza da Silva, Ricella M., Lacle, Miangela M., Koopman, Miriam, Dekker, Jan Willem T., van Tilburg, Arjan, Nuciforo, Paolo, Villalobos Alberú, Xenia, Landolfi, Stefania, Zucchiatti, Adriana, Witteveen, Emma, Bordbar, Arad, Hendriks, Mathijs P., Arensman, René, Natu, Shonali, Maka, Noori, Mesker, Wilma E., Tollenaar, Rob A.E.M., Polack, Meaghan, Smit, Marloes A., van Pelt, Gabi W., Putter, Hein, Meershoek-Kleinenbarg, Elma, Roodvoets, Annet G.H., Crobach, Augustinus S.L.P., Gelderblom, Hans, Fontes e Sousa, Mário, Borralho Nunes, Paula, Cruz, João, Raimundo, Ana, Silva, Nelson, Brito, Maria J., Terpstra, Valeska, Zakhartseva, L.M., Al Dieri, Raed, Fléjou, Jean-François, Feakins, Roger, Dequeker, Els, Vink, Geraldine R., van Krieken, J.Han J.M.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.04.2024; Elsevier
• Subjects: colon cancer; disease-free survival; Original Research; pathology; tumor microenvironment; tumor–stroma ratio; tumor–stroma ratio; pathology; tumor microenvironment; disease-free survival; colon cancer
• ISSN: 2059-7029; 2059-7029
• DOI: 10.1016/j.esmoop.2024.102988

The TNM (tumor–node–metastasis) Evaluation Committee of Union for International Cancer Control (UICC) and College of American Pathologists (CAP) recommended to prospectively validate the cost-effective and robust tumor–stroma ratio (TSR) as an independent prognostic parameter, since high intratumor stromal percentages have previously predicted poor patient-related outcomes. The ‘Uniform Noting for International application of Tumor-stroma ratio as Easy Diagnostic tool' (UNITED) study enrolled patients in 27 participating centers in 12 countries worldwide. The TSR, categorized as stroma-high (>50%) or stroma-low (≤50%), was scored through standardized microscopic assessment by certified pathologists, and effect on disease-free survival (DFS) was evaluated with 3-year median follow-up. Secondary endpoints were benefit assessment of adjuvant chemotherapy (ACT) and overall survival (OS). A total of 1537 patients were included, with 1388 eligible stage II/III patients curatively operated between 2015 and 2021. DFS was significantly shorter in stroma-high (n = 428) than in stroma-low patients (n = 960) (3-year rates 70% versus 83%; P < 0.001). In multivariate analysis, TSR remained an independent prognosticator for DFS (P < 0.001, hazard ratio 1.49, 95% confidence interval 1.17-1.90). As secondary outcome, DFS was also worse in stage II and III stroma-high patients despite adjuvant treatment (3-year rates stage II 73% versus 92% and stage III 66% versus 80%; P = 0.008 and P = 0.011, respectively). In stage II patients not receiving ACT (n = 322), the TSR outperformed the American Society of Clinical Oncology (ASCO) criteria in identifying patients at risk of events (event rate 21% versus 9%), with a higher discriminatory 3-year DFS rate (stroma-high 80% versus ASCO high risk 91%). A trend toward worse 5-year OS in stroma-high was noticeable (74% versus 83% stroma-low; P = 0.102). The multicenter UNITED study unequivocally validates the TSR as an independent prognosticator, confirming worse outcomes in stroma-high patients. The TSR improved current selection criteria for patients at risk of events, and stroma-high patients potentially experienced chemotherapy resistance. TSR implementation in pathology diagnostics and international guidelines is highly recommended as aid in personalized treatment. [Display omitted] •The TSR is a cost-effective and robust histological parameter scored on routine hematoxylin–eosin-stained slides.•This study prospectively validates the independent prognostic effect of the TSR for patients with stage II-III colon cancer.•Stroma-high tumors (i.e. intratumoral stromal percentage >50%) significantly lead to worse DFS.•Stroma-high tumors also exhibit chemotherapy resistance, emphasizing a clinical need for new therapy strategies.•Implementation of the TSR in international guidelines for improved guidance in oncological therapy selection is envisioned.